Generation of an immunodeficient mouse model of tcirg1-deficient autosomal recessive osteopetrosis
Eleonora Palagano,
Sharon Muggeo,
Laura Crisafulli,
Irina L. Tourkova,
Dario Strina,
Stefano Mantero,
Elena Fontana,
Silvia L. Locatelli,
Marta Monari,
Emanuela Morenghi,
Carmelo Carlo-Stella,
John B. Barnett,
Harry C. Blair,
Paolo Vezzoni,
Anna Villa,
Cristina Sobacchi,
Francesca Ficara
Affiliations
Eleonora Palagano
CNR-IRGB, Milan Unit, via Fantoli 16/15, 20138 Milan, Italy; Humanitas Clinical and Research Center IRCCS, via Manzoni 56, 20089 Rozzano, MI, Italy
Sharon Muggeo
CNR-IRGB, Milan Unit, via Fantoli 16/15, 20138 Milan, Italy; Humanitas Clinical and Research Center IRCCS, via Manzoni 56, 20089 Rozzano, MI, Italy
Laura Crisafulli
CNR-IRGB, Milan Unit, via Fantoli 16/15, 20138 Milan, Italy; Humanitas Clinical and Research Center IRCCS, via Manzoni 56, 20089 Rozzano, MI, Italy
Irina L. Tourkova
Veteran's Affairs Medical Center and Department of Pathology, University of Pittsburgh, 4200 Fifth Avenue, Pittsburgh, PA 15260, USA
Dario Strina
CNR-IRGB, Milan Unit, via Fantoli 16/15, 20138 Milan, Italy; Humanitas Clinical and Research Center IRCCS, via Manzoni 56, 20089 Rozzano, MI, Italy
Stefano Mantero
CNR-IRGB, Milan Unit, via Fantoli 16/15, 20138 Milan, Italy; Humanitas Clinical and Research Center IRCCS, via Manzoni 56, 20089 Rozzano, MI, Italy
Elena Fontana
CNR-IRGB, Milan Unit, via Fantoli 16/15, 20138 Milan, Italy; Humanitas Clinical and Research Center IRCCS, via Manzoni 56, 20089 Rozzano, MI, Italy
Silvia L. Locatelli
Department of Oncology and Hematology, Humanitas Clinical and Research Center IRCCS, via Manzoni 56, 20089 Rozzano, MI, Italy
Marta Monari
Clinical Investigation Laboratory, Humanitas Clinical and Research Center IRCCS, via Manzoni 56, 20089 Rozzano, MI, Italy
Emanuela Morenghi
Biostatistics Unit, Humanitas University, Rozzano, MI, Italy
Carmelo Carlo-Stella
Department of Oncology and Hematology, Humanitas Clinical and Research Center IRCCS, via Manzoni 56, 20089 Rozzano, MI, Italy; Department of Biomedical Sciences, Humanitas University, Rozzano, MI, Italy
John B. Barnett
Department of Microbiology, Immunology, and Cell Biology, West Virginia University School of Medicine, Morgantown, WV 26505, USA
Harry C. Blair
Veteran's Affairs Medical Center and Department of Pathology, University of Pittsburgh, 4200 Fifth Avenue, Pittsburgh, PA 15260, USA
Paolo Vezzoni
CNR-IRGB, Milan Unit, via Fantoli 16/15, 20138 Milan, Italy; Humanitas Clinical and Research Center IRCCS, via Manzoni 56, 20089 Rozzano, MI, Italy
Anna Villa
CNR-IRGB, Milan Unit, via Fantoli 16/15, 20138 Milan, Italy; Humanitas Clinical and Research Center IRCCS, via Manzoni 56, 20089 Rozzano, MI, Italy
Cristina Sobacchi
CNR-IRGB, Milan Unit, via Fantoli 16/15, 20138 Milan, Italy; Humanitas Clinical and Research Center IRCCS, via Manzoni 56, 20089 Rozzano, MI, Italy; Corresponding author at: Humanitas Clinical and Research Center – IRCCS, via Manzoni 56, 20089 Rozzano, Italy.
Francesca Ficara
CNR-IRGB, Milan Unit, via Fantoli 16/15, 20138 Milan, Italy; Humanitas Clinical and Research Center IRCCS, via Manzoni 56, 20089 Rozzano, MI, Italy
Background: Autosomal recessive osteopetrosis is a rare skeletal disorder with increased bone density due to a failure in osteoclast bone resorption. In most cases, the defect is cell-autonomous, and >50% of patients bear mutations in the TCIRG1 gene, encoding for a subunit of the vacuolar proton pump essential for osteoclast resorptive activity. The only cure is hematopoietic stem cell transplantation, which corrects the bone pathology by allowing the formation of donor-derived functional osteoclasts. Therapeutic approaches using patient-derived cells corrected ex vivo through viral transduction or gene editing can be considered, but to date functional rescue cannot be demonstrated in vivo because a relevant animal model for xenotransplant is missing. Methods: We generated a new mouse model, which we named NSG oc/oc, presenting severe autosomal recessive osteopetrosis owing to the Tcirg1oc mutation, and profound immunodeficiency caused by the NSG background. We performed neonatal murine bone marrow transplantation and xenotransplantation with human CD34+ cells. Results: We demonstrated that neonatal murine bone marrow transplantation rescued NSG oc/oc mice, in line with previous findings in the oc/oc parental strain and with evidence from clinical practice in humans. Importantly, we also demonstrated human cell chimerism in the bone marrow of NSG oc/oc mice transplanted with human CD34+ cells. The severity and rapid progression of the disease in the mouse model prevented amelioration of the bone pathology; nevertheless, we cannot completely exclude that minor early modifications of the bone tissue might have occurred. Conclusion: Our work paves the way to generating an improved xenograft model for in vivo evaluation of functional rescue of patient-derived corrected cells. Further refinement of the newly generated mouse model will allow capitalizing on it for an optimized exploitation in the path to novel cell therapies.